Business Description
Oramed Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
ORMP.USAORMP.IsraelOJU1.Germany IPO Date
2017-07-12Description
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 5.42 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.2 | |||||
Debt-to-EBITDA | 3.07 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 1.46 | |||||
Beneish M-Score | -1.93 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -37 | |||||
3-Year EPS without NRI Growth Rate | 21.5 | |||||
3-Year FCF Growth Rate | 24.7 | |||||
3-Year Book Growth Rate | 43 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 66.33 | |||||
9-Day RSI | 57.94 | |||||
14-Day RSI | 52.59 | |||||
6-1 Month Momentum % | 3.93 | |||||
12-1 Month Momentum % | -39.03 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.28 | |||||
Quick Ratio | 5.28 | |||||
Cash Ratio | 5.26 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -19.4 | |||||
Shareholder Yield % | -42.09 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -2006.38 | |||||
Net Margin % | 1551.34 | |||||
FCF Margin % | -931.72 | |||||
ROE % | 6.68 | |||||
ROA % | 5.38 | |||||
ROIC % | -21.81 | |||||
ROC (Joel Greenblatt) % | 620.76 | |||||
ROCE % | 6.49 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 8.98 | |||||
PE Ratio without NRI | 8.98 | |||||
Price-to-Owner-Earnings | 12.11 | |||||
PS Ratio | 137.34 | |||||
PB Ratio | 0.57 | |||||
Price-to-Tangible-Book | 0.57 | |||||
EV-to-EBIT | -4.59 | |||||
EV-to-EBITDA | -4.5 | |||||
EV-to-Revenue | -70.8 | |||||
EV-to-Forward-Revenue | 0.91 | |||||
EV-to-FCF | 8.06 | |||||
Price-to-Graham-Number | 0.48 | |||||
Price-to-Net-Current-Asset-Value | 0.67 | |||||
Price-to-Net-Cash | 0.68 | |||||
Earnings Yield (Greenblatt) % | -21.76 | |||||
FCF Yield % | -6.38 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Oramed Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ₪) | 2.513 | ||
EPS (TTM) (₪) | 0.97 | ||
Beta | 0 | ||
Volatility % | 57.69 | ||
14-Day RSI | 52.59 | ||
14-Day ATR (₪) | 0.331673 | ||
20-Day SMA (₪) | 8.24555 | ||
12-1 Month Momentum % | -39.03 | ||
52-Week Range (₪) | 6.612 - 13.68 | ||
Shares Outstanding (Mil) | 40.63 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Oramed Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Oramed Pharmaceuticals Inc Stock Events
Event | Date | Price(₪) | ||
---|---|---|---|---|
No Event Data |
Oramed Pharmaceuticals Inc Frequently Asked Questions
What is Oramed Pharmaceuticals Inc(XTAE:ORMP)'s stock price today?
The current price of XTAE:ORMP is ₪8.57. The 52 week high of XTAE:ORMP is ₪13.68 and 52 week low is ₪6.61.
When is next earnings date of Oramed Pharmaceuticals Inc(XTAE:ORMP)?
The next earnings date of Oramed Pharmaceuticals Inc(XTAE:ORMP) is 2024-08-09 Est..
Does Oramed Pharmaceuticals Inc(XTAE:ORMP) pay dividends? If so, how much?
Oramed Pharmaceuticals Inc(XTAE:ORMP) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |